Dipeptidyl peptidase IV and incident diabetes: The Atherosclerosis Risk in Communities (ARIC) study

Vivian C. Luft, Maria Inês Schmidt, James S. Pankow, Ron C. Hoogeveen, David Couper, Gerardo Heiss, Bruce B. Duncan

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


OBJECTIVE- Dipeptidyl peptidase IV (DPP-IV) is not only important in β-cell function but also has proinflammatory actions. We aimed to investigate whether it could act as a link between low-grade chronic inflammation and diabetes. RESEARCH DESIGN AND METHODS- Using a case-cohort design, we followed 546 middle-aged individuals who developed diabetes and 538 who did not over ∼9 years within the Atherosclerosis Risk in Communities study. RESULTS- In weighted analyses, the correlation between DPP-IV levels and anthropometric, inflammatory, or metabolic variables was minimal (Spearman correlations <0.11). Those who developed diabetes had mean DPP-IV values similar to those who did not (P = 0.18). Individuals in the highest quartile of DPP-IV were not at greater risk of diabetes (hazard ratio 0.88 [95% CI 0.62-1.24]) in Cox proportional hazards models adjusting for age, sex, race, study center, and multiple additional diabetes risk factors. CONCLUSIONS- Fasting DPP-IV levels do not appear to predict incident diabetes.

Original languageEnglish (US)
Pages (from-to)1109-1111
Number of pages3
JournalDiabetes care
Issue number5
StatePublished - May 2010


Dive into the research topics of 'Dipeptidyl peptidase IV and incident diabetes: The Atherosclerosis Risk in Communities (ARIC) study'. Together they form a unique fingerprint.

Cite this